Novartis presents a novel covalent inhibitor of mutant-selective EGFR for the treatment of NSCLC April 11, 2014
Bristol-Myers Squibb presents first-in-human results for the anti-atherosclerosis agent BMS-962476 April 11, 2014
ASP-8273 efficiently induces and maintains tumor growth regression in mutant EGFR NSCLC models April 11, 2014
BLU-9931 shows antitumor activity in vitro and in in vivo HCC models with aberrant FGF-19 April 10, 2014
RSS